These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
771 related articles for article (PubMed ID: 25395481)
1. ▼Bedaquiline for multidrug-resistant tuberculosis. Drug Ther Bull; 2014 Nov; 52(11):129-32. PubMed ID: 25395481 [TBL] [Abstract][Full Text] [Related]
2. Provisional CDC guidelines for the use and safety monitoring of bedaquiline fumarate (Sirturo) for the treatment of multidrug-resistant tuberculosis. Centers for Disease Control and Prevention MMWR Recomm Rep; 2013 Oct; 62(RR-09):1-12. PubMed ID: 24157696 [TBL] [Abstract][Full Text] [Related]
3. Identification of patients who could benefit from bedaquiline or delamanid: a multisite MDR-TB cohort study. Bonnet M; Bastard M; du Cros P; Khamraev A; Kimenye K; Khurkhumal S; Hayrapetyan A; Themba D; Telnov A; Sanchez-Padilla E; Hewison C; Varaine F Int J Tuberc Lung Dis; 2016 Feb; 20(2):177-86. PubMed ID: 26792469 [TBL] [Abstract][Full Text] [Related]
4. Management of multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis: current status and future prospects. Yew WW Kekkaku; 2011 Jan; 86(1):9-16. PubMed ID: 21401001 [TBL] [Abstract][Full Text] [Related]
5. Recent controversies about MDR and XDR-TB: Global implementation of the WHO shorter MDR-TB regimen and bedaquiline for all with MDR-TB? Dheda K; Cox H; Esmail A; Wasserman S; Chang KC; Lange C Respirology; 2018 Jan; 23(1):36-45. PubMed ID: 28850767 [TBL] [Abstract][Full Text] [Related]
6. Bedaquiline: a novel diarylquinoline for multidrug-resistant tuberculosis. Chahine EB; Karaoui LR; Mansour H Ann Pharmacother; 2014 Jan; 48(1):107-15. PubMed ID: 24259600 [TBL] [Abstract][Full Text] [Related]
7. Incremental Cost Effectiveness of Bedaquiline for the Treatment of Rifampicin-Resistant Tuberculosis in South Africa: Model-Based Analysis. Schnippel K; Firnhaber C; Conradie F; Ndjeka N; Sinanovic E Appl Health Econ Health Policy; 2018 Feb; 16(1):43-54. PubMed ID: 28980217 [TBL] [Abstract][Full Text] [Related]
8. Bedaquiline in the treatment of multidrug- and extensively drug-resistant tuberculosis. Pym AS; Diacon AH; Tang SJ; Conradie F; Danilovits M; Chuchottaworn C; Vasilyeva I; Andries K; Bakare N; De Marez T; Haxaire-Theeuwes M; Lounis N; Meyvisch P; Van Baelen B; van Heeswijk RP; Dannemann B; Eur Respir J; 2016 Feb; 47(2):564-74. PubMed ID: 26647431 [TBL] [Abstract][Full Text] [Related]
9. Combined Use of Delamanid and Bedaquiline to Treat Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis: A Systematic Review. Migliori GB; Pontali E; Sotgiu G; Centis R; D'Ambrosio L; Tiberi S; Tadolini M; Esposito S Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28178199 [TBL] [Abstract][Full Text] [Related]
10. Tradeoffs in Introduction Policies for the Anti-Tuberculosis Drug Bedaquiline: A Model-Based Analysis. Kunkel A; Cobelens FG; Cohen T PLoS Med; 2016 Oct; 13(10):e1002142. PubMed ID: 27727274 [TBL] [Abstract][Full Text] [Related]
11. Delamanid: From discovery to its use for pulmonary multidrug-resistant tuberculosis (MDR-TB). Liu Y; Matsumoto M; Ishida H; Ohguro K; Yoshitake M; Gupta R; Geiter L; Hafkin J Tuberculosis (Edinb); 2018 Jul; 111():20-30. PubMed ID: 30029909 [TBL] [Abstract][Full Text] [Related]
12. Bedaquiline for the treatment of resistant tuberculosis: promises and pitfalls. Kakkar AK; Dahiya N Tuberculosis (Edinb); 2014 Jul; 94(4):357-62. PubMed ID: 24841672 [TBL] [Abstract][Full Text] [Related]
13. Multi and extensively drug-resistant pulmonary tuberculosis: advances in diagnosis and management. Pontali E; Visca D; Centis R; D'Ambrosio L; Spanevello A; Migliori GB Curr Opin Pulm Med; 2018 May; 24(3):244-252. PubMed ID: 29470252 [TBL] [Abstract][Full Text] [Related]
14. [Two news drugs (ivacaftor & bedaquiline), one biomarker (florbetapir) and a re-positioned drug (propranolol) on the market]. Monneret C Ann Pharm Fr; 2014 Jul; 72(4):229-37. PubMed ID: 24997884 [TBL] [Abstract][Full Text] [Related]
15. The endTB observational study protocol: treatment of MDR-TB with bedaquiline or delamanid containing regimens. Khan U; Huerga H; Khan AJ; Mitnick CD; Hewison C; Varaine F; Bastard M; Rich M; Franke MF; Atwood S; Khan PY; Seung KJ BMC Infect Dis; 2019 Aug; 19(1):733. PubMed ID: 31429722 [TBL] [Abstract][Full Text] [Related]
16. Management of drug resistantTB in patients with HIV co-infection. Pontali E; Sotgiu G; Centis R; D'Ambrosio L; Spanevello A; Migliori GB Expert Opin Pharmacother; 2015; 16(18):2737-50. PubMed ID: 26478945 [TBL] [Abstract][Full Text] [Related]
17. TMC207 becomes bedaquiline, a new anti-TB drug. Palomino JC; Martin A Future Microbiol; 2013 Sep; 8(9):1071-80. PubMed ID: 24020736 [TBL] [Abstract][Full Text] [Related]
18. Initial experience of bedaquiline use in a series of drug-resistant tuberculosis patients from India. Udwadia ZF; Amale RA; Mullerpattan JB Int J Tuberc Lung Dis; 2014 Nov; 18(11):1315-8. PubMed ID: 25299863 [TBL] [Abstract][Full Text] [Related]
19. Compassionate use of bedaquiline for the treatment of multidrug-resistant and extensively drug-resistant tuberculosis: interim analysis of a French cohort. Guglielmetti L; Le Dû D; Jachym M; Henry B; Martin D; Caumes E; Veziris N; Métivier N; Robert J; Clin Infect Dis; 2015 Jan; 60(2):188-94. PubMed ID: 25320286 [TBL] [Abstract][Full Text] [Related]
20. Prevalence of extensively drug-resistant tuberculosis among patients with multidrug-resistant tuberculosis: a retrospective hospital-based study. Sharma SK; George N; Kadhiravan T; Saha PK; Mishra HK; Hanif M Indian J Med Res; 2009 Oct; 130(4):392-5. PubMed ID: 19942741 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]